^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Pleiotropic pathway modifier

    Related drugs:
    1year
    A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov)
    P1, N=15, Terminated, Celgene | Completed --> Terminated; Replaced it with another clinical trial.
    Trial termination
    |
    avadomide (CC-122)
    almost2years
    Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=174, Terminated, Celgene | Active, not recruiting --> Terminated; Replaced with another clinical trial.
    Trial termination
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • avadomide (CC-122) • onatasertib (ATG-008) • spebrutinib (CC-292)
    almost2years
    A Rollover Study of CC-122 (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    avadomide (CC-122)
    almost2years
    Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma (clinicaltrials.gov)
    P1, N=271, Completed, Celgene | Active, not recruiting --> Completed | Phase classification: P1a/1b --> P1
    Trial completion • Phase classification
    |
    avadomide (CC-122)
    2years
    Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=174, Active, not recruiting, Celgene | Phase classification: P1b --> P1 | Trial completion date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2023 --> Jan 2024
    Phase classification • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • avadomide (CC-122) • onatasertib (ATG-008) • spebrutinib (CC-292)
    2years
    Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups (ASH 2023)
    Methods Data used in this study included RNA (n=143) and whole exome (n=126) sequencing data from available FFPE tumor samples at the time of a relapse (any line of treatment, r1-r10 relapse timepoints included in analysis, one per patient), consented to the Molecular Epidemiology Resource (n=61), banked in the Mayo Lymphoma Biobank (n=50), or consented to the CC-122-ST-001 clinical trial (n=32, NCT01421524). In summary, we show for the first time that rrDLBCL patients can be classified into four gene expression clusters that are associated with distinct pathway, TME, and genetic programs. These clusters should now be tested to learn if they can help select patients for newer therapies for rrDLBCL such as CAR-T and bispecific antibodies.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • BCL7A (BAF Chromatin Remodeling Complex Subunit BCL7A)
    |
    BCL7A mutation
    |
    avadomide (CC-122) • fenretinide nanoparticle (ST-001 nanoFenretinide)
    2years
    A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (clinicaltrials.gov)
    P1b, N=75, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive • MYC overexpression • MYC rearrangement
    |
    Gazyva (obinutuzumab) • avadomide (CC-122)
    over2years
    Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. (PubMed, Cancer Chemother Pharmacol)
    Our findings suggest that avadomide could be a novel therapeutic option to overcome gemcitabine resistance in patients with PDAC.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    gemcitabine • thalidomide • avadomide (CC-122)
    over2years
    A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (clinicaltrials.gov)
    P1b, N=75, Active, not recruiting, Celgene | Trial completion date: Feb 2023 --> Aug 2023 | Trial primary completion date: Feb 2023 --> Aug 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive • MYC overexpression • MYC rearrangement
    |
    Gazyva (obinutuzumab) • avadomide (CC-122)
    over2years
    Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma (clinicaltrials.gov)
    P1a/1b, N=271, Active, not recruiting, Celgene | Trial completion date: Apr 2023 --> Jul 2023 | Trial primary completion date: Apr 2023 --> Jul 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    avadomide (CC-122)
    over2years
    Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma (clinicaltrials.gov)
    P1b, N=174, Active, not recruiting, Celgene | Trial completion date: Apr 2023 --> Jul 2023 | Trial primary completion date: Apr 2023 --> Jul 2023
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • avadomide (CC-122) • onatasertib (ATG-008) • spebrutinib (CC-292)
    over2years
    A Rollover Study of CC-122 (clinicaltrials.gov)
    P1, N=12, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    avadomide (CC-122)